HSP90AA1 and cancer: Most previous studies regarded Hsp90 chaperone as one machinery and inhibited Hsp90 activities in cancer models and clinical trials with pan-Hsp90i, which may largely account for the disappointing clinical performance of Hsp90 inhibition in cancer treatment so far.